Risk of venous thromboembolism in lung cancer

Current Opinion in Pulmonary Medicine

Volumn 13, Issue 5, 2007, Pages 362-367

  Tesselaar, Margot E T ^a   Osanto, Susanne ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Carcinoma; Embolism and thrombosis; Lung neoplasms; Nonsmall cell lung; Small cell; Venous thrombosis

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; APRINOCARSEN; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ERYTHROPOIETIN; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; IRINOTECAN; NAVELBINE; PACLITAXEL; PLACEBO; PRINOMASTAT; SEMAXANIB; TAXANE DERIVATIVE; THALIDOMIDE; THROMBOPLASTIN; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR;

ADD ON THERAPY; AORTA THROMBOSIS; BLEEDING; BLOOD CLOTTING; CANCER PATIENT; CANCER STAGING; CIRCULATION; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE SEVERITY; HISTOPATHOLOGY; HUMAN; INCIDENCE; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LUNG SMALL CELL CANCER; METASTASIS; POPULATION RESEARCH; REVIEW; RISK FACTOR; SQUAMOUS CELL CARCINOMA; THROMBOCYTE COUNT; THROMBOGENESIS; THROMBOSIS; TUMOR CELL; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM;

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM METASTASIS; NEOPLASM STAGING; POSTOPERATIVE COMPLICATIONS; PULMONARY EMBOLISM; RISK FACTORS; VENOUS THROMBOSIS;

EID: 34748888394     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e328209413c     Document Type: Review

References (46)

1. Nordstrom M, Lindblad B, Bergqvist D, Kjellstrom T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med 1992; 232:155-160.
2. Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 158:585-593.
3. Naess IA, Christiansen SC, Romundstad P, et al. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007; March 15 [Epub ahead of print]. • Incidence and mortality of a first venous thrombosis in the general population in Norway aged 20 years and older (n = 94 194) is reported in this large population-based study.
4. Doggen CJ, Smith NL, Lemaitre RN, et al. Serum lipid levels and the risk of venous thrombosis. Arterioscler Thromb Vasc Biol 2004; 24:1970-1975.
5. Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation 2003; 107 (23 Suppl 1):I17-I21.
6. Trousseau A. Phlegmasia alba dolens. In: Clinique medicale de l'Hotel-dieu de Paris. Paris: JB Balliere et Fils; 1865. pp. 654-715.
7. Mao C, Domenico DR, Kim K, et al. Observations on the developmental patterns and the consequences of pancreatic exocrine adenocarcinoma. Findings of 154 autopsies. Arch Surg 1995; 130:125-134.
8. Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost 2002; 87:575-579.
9. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55:10-30.
10. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999; 78:285-291.
11. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293:715-722.
12. Rickles FR. Thrombosis and lung cancer. Am Rev Respir Dis 1989; 140:573-575.
13. Gabazza EC, Taguchi O, Yamakami T, et al. Evaluating prethrombotic state in lung cancer using molecular markers. Chest 1993; 103:196-200.
14. Blom JW, Osanto S, Rosendaal FR. The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma. J Thromb Haemost 2004; 2:1760-1765.
15. Lieberman JS, Borrero J, Urdaneta E, Wright IS. Thrombophlebitis and cancer. JAMA 1961; 177:542-545.
16. Sack GH Jr, Levin J, Bell WR. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore) 1977; 56:1-37.
17. Levi D, Tagalakis V, Cohen V, et al. The risk of deep vein thrombosis in lung cancer patients [abstract]. Proceedings of the American Thoracic Society Annual Meeting, 17-22 May 2006, Atlanta. New York: American Thoracic Society; 2006. Abstract 7159.
18. White RH, Chew HK, Zhou H, et al. Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. Arch Intern Med 2005; 165:1782-1787.
19. Falanga A, Rickles FR. Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost 1999; 25:173-182.
20. Yu JL, May L, Lhotak V, et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood 2005; 105:1734-1741.
21. Falanga A, Ofosu FA, Cortelazzo S, et al. Preliminary study to identify cancer patients at high risk of venous thrombosis following major surgery. Br J Haematol 1993; 85:745-750.
22. Callander NS, Varki N, Rao LV. Immunohistochemical identification of tissue factor in solid tumors. Cancer 1992; 70:1194-1201.
23. Ornstein DL, Zacharski LR, Memoli VA, et al. Coexisting macrophage-associated fibrin formation and tumor cell urokinase in squamous cell and adenocarcinoma of the lung tissues. Cancer 1991; 68:1061-1067.
24. Sawada M, Miyake S, Ohdama S, et al. Expression of tissue factor in nonsmall-cell lung cancers and its relationship to metastasis. Br J Cancer 1999; 79 (3-4):472-477.
25. Sato T, Tsujino I, Ikeda D, et al. Trousseau's syndrome associated with tissue factor produced by pulmonary adenocarcinoma. Thorax 2006; 61:1009-1010. • This is the first report of a patient with Trousseau's syndrome in whom tissue factor originating from lung cancer appears to be responsible for his recurrent venous thrombosis.
26. Tesselaar ME, Romijn FP, van der Linden I, et al. Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost 2007; 5:520-527. •• This is the first study to demonstrate that microparticle-associated tissue factor activity and expression of MUC1 on microparticles are associated with development of thrombosis in cancer patients with mucinous adenocarcinomas.
27. Del Conde I, Bharwani LD, Dietzen DJ, et al. Microvesicle- associated tissue factor and Trousseau's syndrome. J Thromb Haemost 2007; 5:70-74. • In this case report, a significantly elevated plasma tissue factor concentration was found in a patient with a giant-cell lung carcinoma with a severe form of Trousseau's syndrome and almost all of the tissue factor was associated with cell-derived microparticles.
28. White RH, Zhou H, Romano PS. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost 2003; 90:446-455.
29. Kalweit G, Huwer H, Volkmer I, et al. Pulmonary embolism: a frequent cause of acute fatality after lung resection. Eur J Cardiothorac Surg 1996; 10:242-246.
30. ENOXACAN Study Group. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. Br J Surg 1997; 84:1099-1103.
31. McLeod RS, Geerts WH, Sniderman KW, et al. Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery: results of the Canadian colorectal DVT prophylaxis trial: a randomized, double-blind trial. Ann Surg 2001; 233:438-444.
32. Burri E, Duwe J, Kull C, et al. Pulmonary vein thrombosis after lower lobectomy of the left lung. J Cardiovasc Surg (Torino) 2006; 47:609-612.
33. Nagasaki F, Flehinger BJ, Martini N. Complications of surgery in the treatment of carcinoma of the lung. Chest 1982; 82:25-29.
34. Mason DP, Quader MA, Blackstone EH, et al. Thromboembolism after pneumonectomy for malignancy: an independent marker of poor outcome. J Thorac Cardiovasc Surg 2006; 131:711-718. This study determined the prevalence, location, management, timing, and risk factors for postoperative morbidity and mortality after pneumonectomy in 336 patients who underwent pneumonectomy for malignancy. Venous thromboembolism was found to be much more common then previously reported.
35. Paesmans M. Benefits of chemotherapy for quality of life in patients with advanced nonsmall-cell lung cancer. Curr Opin Oncol 2002; 14:389-393.
36. Crivellari G, Monfardini S, Stragliotto S, et al. Increasing chemotherapy in small-cell lung cancer: from dose intensity and density to megadoses. Oncologist 2007; 12:79-89.
37. Zecchina G, Ghio P, Bosio S, et al. Reactive thrombocytosis might contribute to chemotherapy-related thrombophilia in patients with lung cancer. Clin Lung Cancer 2007; 8:264-267. • In this study early hemostatic alterations (i.e. blood cell count, prothrombin time, partial thromboplastin time, fibrinogen, antithrombin, D-dimers, protein C, protein S, homocysteine, folates, vitamin B12, and activated protein-C resistance) and factor V Leiden and FII G20210A mutations were assessed as risk factors for thrombosis in patients undergoing chemotherapy for lung cancer. This study shows that chemotherapy-related thrombosis, but not alterations of coagulation inhibitors or activation of disseminated intravascular coagulopathy/fibrinolysis, seemed to play a role in triggering thrombotic complications.
38. Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000; 160:809-815.
39. Numico G, Garrone O, Dongiovanni V, et al. Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. Cancer 2005; 103:994-999.
40. Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 2005; 104:2822-2829.
41. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for nonsmall-cell lung cancer. N Engl J Med 2006; 355:2542-2550. •• This well-designed randomized prospective study in 878 patients with recurrent or advanced NSCLC who were treated with paclitaxel plus carboplatin with or without bevacizumab showed that addition of bevacizumab was associated with a significant survival benefit but also with an increase in treatment-related deaths.
42. Kuenen BC, Rosen L, Smit EF, et al. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol 2002; 20:1657-1667.
43. Anscher MS, Garst J, Marks LB, et al. Assessing the ability of the antiangiogenic and anticytokine agent thalidomide to modulate radiation-induced lung injury. Int J Radiat Oncol Biol Phys 2006; 66:477-482.
44. Yoon S, Schmassmann-Suhijar D, Zuber M, et al. Chemotherapy with bevacizumab, irinotecan, 5-fluorouracil and leucovorin (IFL) associated with a large, embolizing thrombus in the thoracic aorta. Ann Oncol 2006; 17:1851-1852.
45. Behrendt CE, Ruiz RB. Venous thromboembolism among patients with advanced lung cancer randomized to prinomastat or placebo, plus chemotherapy. Thromb Haemost 2003; 90:734-737.
46. Paz-Ares L, Douillard JY, Koralewski P, et al. Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage nonsmall-cell lung cancer. J Clin Oncol 2006; 24:1428-1434.•• In this phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-α antisense oligonucleotide, in patients (n = 670) with advanced-stage NSCLC, addition of aprinocarsen to standard chemotherapy did not enhance survival but significantly increased grade 3 and 4 toxicities including thrombocytopenia, epistaxis and thromboembolism.